Innovative strategies in the diagnosis and treatment of tuberculosis: a patent review (2014–2017)

References

• World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. (WHO/HTM/TB/2017.23).
   Google Scholar
• World Health Organization. Global tuberculosis report 2016. Geneva: World Health Organization; 2016. (WHO/HTM/TB/2016.13).
   Google Scholar
• Patil TS, Deshpande AS, Deshpande S, et al. Targeting pulmonary tuberculosis using nanocarrier-based dry powder inhalation: current status and futuristic need. J Drug Target. 2018;1–16. DOI:10.1080/1061186X.2018.1455842.
   PubMedGoogle Scholar
• Patil TS, Deshpande AS. Nanostructured lipid carriers-based drug delivery for treating various lung diseases: a state‐of‐the‐art review. Int J Pharm. 2018;547(1–2):209–225.
   PubMedGoogle Scholar
• Patil K, Bagade S, Bonde S, et al. Recent therapeutic approaches for the management of tuberculosis: challenges and opportunities. Biomed Pharmacother. 2018;99(2018):735–745.
   PubMedGoogle Scholar
• Are we failing today’s TB patients? It’s time for better treatment options [Internet]. Medicines Patent Pool; 2018 Mar 22; [cited 2018 Jun 10]; [about 1 screen]. Available from: https://medicinespatentpool.org/mpp-media-post/are-we-failing-todays-tb-patients-its-time-for-better-treatment-options/
   Google Scholar
• The global plan to end TB, 2016–2020 [Internet]. Geneva: Stop TB Partnership; 2015; [cited 2018 Jun 10]; [about 1 screen]. Available from: http://www.stoptb.org/global/plan/
   Google Scholar
• Caulfield AJ, Wengenack NL. Diagnosis of active tuberculosis disease: from microscopy to molecular techniques. J Clin Tuber Other Mycobact Dis. 2016;4(2016):33–43.
   Google Scholar
• Childhood TB [Internet]. World Health Organization; 2017 Mar 24; [cited 2018 Jun 10; [about 1 screen]. Available from: http://www.who.int/tb/areas-of-work/children/
   Google Scholar
• Lu Y, Wang L, Duanmu H, et al. Handbook of global tuberculosis control. Boston: Springer; 2017.
   Google Scholar
• Brigden G, Castro JL, Ditiu L, et al. Tuberculosis and antimicrobial resistance–new models of research and development needed. Bull World Health Organ. 2017;95(5):315.
   PubMed Web of Science ®Google Scholar
• Lancet feature on need for urgent new drug development cites The Life Prize [Internet]. The Union; 2017 Nov 7 cited 2018 Jun 10; [about 1 screen]. Available from: https://www.theunion.org/news-centre/news/lancet-feature-cites-the-life-prize
   Google Scholar
• The Medicines Patent Pool announces first licence for tuberculosis treatment [internet]. Medicines Patent Pool; 2017 Jan 25 cited 2018 Jun 10; [about 1 screen]. Available from: https://medicinespatentpool.org/mpp-media-post/the-medicines-patent-pool-announces-first-licence-for-tuberculosis-treatment/
   Google Scholar
• The Union welcomes the Medicines Patent Pool’s first open licence agreement for tuberculosis treatment [Internet]. The Union; 2017 Jan 25; [cited 2018 Jun 10]; [about 1 screen]. Available from: https://www.theunion.org/news-centre/news/the-union-welcomes-the-medicines-patent-pools-first-open-licence-agreement-for-tuberculosis-treatment
   Google Scholar
• World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. Geneva: World Health Organization; 2016. (WHO/HTM/TB/2016.07) cited 2018 Jun 10. Available from: http://www.who.int/tb/publications/lpa-mdr-diagnostics/en/
   Google Scholar
• Boehme CC, Nabeta P, Henostroza G, et al. Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J Clin Microbiol. 2007;45(6):1936–1940.
   PubMed Web of Science ®Google Scholar
• Shengxiang GE, Yongliang L, Mengyuan C, et al. Method and kit for diagnosis of active tuberculosis. WO2017125007. 2017.
   Google Scholar
• Andreevna SD, Sergeevich SA, Evgenevich SB. Method for choosing therapeutic approach for patents with newly diagnosed infiltrative pulmonary tuberculosis. RU2602683. 2016.
   Google Scholar
• O’Garra A, Bloom C, Berry MPR, et al. Early detection of tuberculosis treatment response. US 2015/0133469 A1. 2015.
   Google Scholar
• Guanjing Z, Xingming C, Xinke GE. Wearable device for monitoring early symptoms of pulmonary tuberculosis. WO2017000587. 2017.
   Google Scholar
• Shantha TR. Innovative methods of treatmenting tuberculosis. US20160074480. 2016.
   Google Scholar
• Brickner SJ, Nuermberger E, Stover CK. Combination therapy for tuberculosis. US2016/0220578 A1. 2016.
   Google Scholar
• Karakousis P, Ciaran S, Richard P, et al. Lipid-modulating agents as adjunctive therapy for tuberculosis. WO/2015/179500. 2015.
   Google Scholar
• Liu Q. Traditional Chinese medicine composition for treating pulmonary tuberculosis and acupoint combined acupuncture application. CN104435103A. 2015.
   Google Scholar
• Liu J, Wei Z. Traditional Chinese medicine for treating lung Yin-deficiency type tuberculosis and preparation method thereof. CN 105943661. 2016.
   Google Scholar
• Amith K, Bindu M, Kum P, et al. Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation. US 2016/0158226 A1. 2016.
   Google Scholar
• Dilip P, Kum P, Praveen K, et al. Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation. US 2016/0184231 A1. 2016.
   Google Scholar
• Dilip P, Kum P, Praveen K, et al. Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation. US 2016/0158157 A1. 2016.
   Google Scholar
• Iglesias PJC, Riera IA, Reyes B, et al. Liposome formulation suitable for treating or preventing tuberculosis. US 2015/0050327 A1. 2015.
   Google Scholar
• Changying L. Preparation method of rifapentine-carried polycaprolactone microspheres. CN 106420663 (A). 2017.
   Google Scholar
• Gobardhan D, Mrutyunjay S. A pharmaceutical combination for treating tuberculosis. WO 2014/170820 A2. 2014.
   Google Scholar
• Ekaterina NM, Vladimir AN, Yury NC. Method for correction of isoniazid-induced hepatotoxic reactions. RU0002601919. 2016.
   Google Scholar
• Ekaterina NM, Vladimir AN, Yury NC, et al. 6. Method for prevention of complications induced by isoniazid. RU 0002597788. 2016.
   Google Scholar
• Alexandrovna AV, Mikhailovna FI, Diegovna EC, et al. 9. Method of treating patients with destructive forms of pulmonary tuberculosis. RU 0002587332. 2016.
   Google Scholar
• Alexandrovna AV, Mikhailovna FI, Georgievna KG. Method for treatment of patients with tuberculosis of lungs. RU0002621875 (C1). 2017.
   Google Scholar
• Dunn JJ, Starke JR, Revell PA. Laboratory diagnosis of Mycobacterium tuberculosis infection and disease in children. J Clin Microbiol. 2016;54(6):1434–1441.
   PubMed Web of Science ®Google Scholar